172@29@16@17!~!172@29@0@53!~!|commonstore|commonfiles|moneycontrol_header.php?cid=0&s_cid=0&radar_off=0&is_revamped_header=1&is_responsive=1&sec=SWOT_DETAIL&priceinter=1&frommc=1!~!www|moneycontrol|com!~!|commonstore|commonfiles|moneycontrol_header.php!~!is_mobile=false
Moneycontrol
SENSEX NIFTY
you are here:

Ipca Laboratories Ltd.

BSE: 524494 | NSE: IPCALAB |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE571A01020 | SECTOR: Pharmaceuticals

BSE Live

Oct 22, 09:45
2041.60 -33.80 (-1.63%)
Volume
AVERAGE VOLUME
5-Day
5,651
10-Day
5,670
30-Day
14,624
750
  • Prev. Close

    2075.40

  • Open Price

    2056.30

  • Bid Price (Qty.)

    2043.85 (5)

  • Offer Price (Qty.)

    2046.75 (12)

NSE Live

Oct 22, 09:45
2045.55 -30.20 (-1.45%)
Volume
AVERAGE VOLUME
5-Day
150,215
10-Day
146,658
30-Day
244,507
27,419
  • Prev. Close

    2075.75

  • Open Price

    2060.00

  • Bid Price (Qty.)

    2045.60 (1)

  • Offer Price (Qty.)

    2046.10 (4)

Strengths (14)
  • Company with high TTM EPS Growth
  • Strong QoQ EPS Growth in recent results
  • Effectively using its capital to generate profit - RoCE improving in last 2 years
  • Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
  • Efficient in managing Assets to generate Profits - ROA improving since last 2 year
  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
  • Company with Low Debt
  • Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
  • Annual Net Profits improving for last 2 years
  • Book Value per share Improving for last 2 years
  • Company with Zero Promoter Pledge
  • FII / FPI or Institutions increasing their shareholding
  • Companies with rising net profit margins - quarterly as well as TTM basis
Weaknesses (2)
  • Companies with growing costs YoY for long term projects
  • Declining Net Cash Flow : Companies not able to generate net cash
Opportunities (5)
  • Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes
  • Brokers upgraded recommendation or target price in the past three months
  • Negative to Positive growth in Sales and Profit with Strong Price momentum
  • Highest Recovery from 52 Week Low
  • Insiders bought stocks
Threats (1)
  • Insiders sold stocks
Powered by Trendlyne
Note :Financial Information is based on Consolidated numbers.